Form 4: Elanco CEO Jeffrey Simmons Reports Stock Transactions

Elanco Animal Health CEO Jeffrey Simmons reports disposition of shares to cover tax liabilities and holdings in a revocable trust.

Summary

• On March 5, 2024, Jeffrey N. Simmons, CEO and Director of Elanco Animal Health Inc., reported a transaction involving the disposition of 11,012 shares of common stock to cover tax liabilities.
• The shares were disposed of at a price of $15.99 per share.
• Following the transaction, Simmons directly owns 1,356,455 shares of Elanco common stock.
• Simmons also indirectly owns 45,000 shares through a revocable trust.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing detailing stock transactions by an executive. It doesn't inherently convey positive or negative sentiment.

Industry Context

This filing is a routine disclosure of insider transactions, which are common for executives of publicly traded companies. It provides transparency into the trading activities of company leadership.

Comparison to Industry Standards

• Form 4 filings are standard practice for corporate insiders and are required by the SEC to ensure transparency.
• Similar filings are made by executives at companies like Zoetis and Merck Animal Health when they engage in stock transactions.

Stakeholder Impact

• The transaction has a minimal direct impact on shareholders, as it is a routine sale of shares by an executive to cover tax obligations.

Key Dates